Identifying High Affinity TCRs via PD-1 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to identify and characterize T cell receptor (TCR) sequences and their affinity simultaneously, which is crucial for understanding the spatiotemporal fate and protective capacity of tumor-specific T cells.
Innovation Solution
A method involving the determination of PD-1, CD226, CD82, CD39, or ICOS expression levels in peripheral blood samples to identify T cells with high affinity TCRs, and subsequent isolation and characterization of these T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional methods are used to study TCR affinity, then T cell fate can be tracked, but TCR sequences and their affinity cannot be characterized simultaneously
Solution Approach 1:
The patent combines TCR sequencing and affinity measurement into a single integrated method. By using single-cell RNA sequencing to obtain TCR sequences and simultaneously measuring PD-1 expression levels as an affinity indicator, the method eliminates the need for separate experiments, thereby reducing overall complexity while achieving simultaneous characterization of both TCR sequences and their functional properties.
Solution Approach 2:
The patent introduces PD-1 expression level as an intermediary marker to indirectly measure TCR affinity. Instead of directly measuring TCR binding strength, which would require complex biochemical assays, the method uses PD-1 expression as a surrogate indicator that correlates with TCR affinity, simplifying the measurement process while maintaining measurement precision.
2Reliability
If T cells are isolated from tumor tissue, then tumor-specific T cells can be obtained, but the process is invasive and difficult
Solution Approach 1:
The patent uses PD-1 expression level as an intermediary marker to identify and isolate high-affinity TCR T cells from peripheral blood. This approach allows researchers to obtain tumor-specific T cells without directly accessing tumor tissue, using the peripheral blood as a surrogate source that can be easily accessed while maintaining the ability to identify functionally relevant T cell populations.
Solution Approach 2:
The patent replaces the mechanical/invasive process of tumor tissue biopsy with a blood draw and molecular marker-based identification system. By substituting direct tissue access with circulating blood analysis and PD-1 expression measurement, the method maintains reliability in identifying tumor-specific T cells while dramatically improving ease of operation and sample accessibility.
3Productivity
If high cell numbers are transferred in adoptive transfer experiments, then T cell response can be observed, but the physiological relevance is reduced
Solution Approach 1:
The patent uses PD-1 expression levels to identify and enrich for high-affinity TCR T cells, which are more likely to be functionally relevant at lower numbers. By partially selecting for the most promising T cell clones based on their affinity markers, the method achieves sufficient T cell response detectability while using lower cell numbers that better reflect physiological conditions, thereby maintaining reliability.
4Loss of information
If TCR affinity is assumed to determine T cell fate, then protective capacity can be predicted, but experimental evidence is scarce
Solution Approach 1:
The patent establishes a feedback loop where PD-1 expression levels (measured in peripheral blood) are used to predict T cell affinity and fate, which can then be experimentally verified through T cell isolation and functional assays. This feedback mechanism allows researchers to test and refine the relationship between TCR affinity and T cell spatiotemporal fate, accumulating experimental evidence to support or challenge the initial assumption.
Data Source
AI summary
The present invention relates to a method of identifying one or more T cells, as well as method of isolating one or more T cells. Further, the invention relates to a method of identifying one or more TCR, a nucleic acid molecule comprising a nucleic acid sequence encoding the TCR identified by the methods of the invention. The invention also relates to a method of generating one or more immune cells. The invention also relates to a host cell comprising a nucleic molecule encoding a TCR identified by the invention or generated by a method of the invention. The invention also relates to a pharmaceutical composition comprising a cell of the invention, or a cell of the invention for use in therapy. Finally, the invention also relates to a method of diagnosing cancer.